Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Test Predicts Chronic Lung Disease in Preterm Babies

By LabMedica International staff writers
Posted on 09 Aug 2024

Bronchopulmonary dysplasia (BPD) is a condition that impacts 65% of preterm infants, leading to chronic lung disease and neurodevelopmental impairments that persist throughout life. More...

BPD typically arises when premature infants require respiratory support and prolonged oxygen therapy, which can damage their developing lungs. Currently, options for predicting, preventing, and treating BPD are inadequate. Diagnoses are often not confirmed until 36 weeks post-menstrual age, delaying interventions that could reduce lung damage and enhance respiratory health. Existing early prediction tools do not effectively address the underlying pathology of the disease. However, timely lung protective measures can modify BPD incidence. More precise care could be administered if the likelihood of lung damage and other complications in these infants were known sooner. Researchers have now developed a blood test that can predict which preterm infants will go on to develop chronic lung disease, facilitating earlier intervention and more focused treatment strategies.

The research, led by Murdoch Children’s Research Institute (MCRI, Victoria, Australia), found that variations in specific blood proteins, combined with factors like gestational age, birth weight, and sex, can accurately predict BPD within the first 72 hours of life. This study involved testing 493 proteins in the blood of 23 infants born before 29 weeks' gestation. Notably, alterations in 49 proteins were observed in infants who later exhibited BPD, with some changes detectable within just four hours after birth. The study, published in the American Journal of Respiratory Cell and Molecular Biology, provides a detailed overview of the early biological shifts occurring in infants with BPD, offering critical insights into the disease’s early progression. The researchers are now aiming to develop a comprehensive tool for assessing lung injury, which could be utilized across all preterm infants in Neonatal Intensive Care Units (NICU) or special care nurseries to evaluate the risk of developing BPD.

“The tool, including a blood test, would provide clinicians with the ability to guide respiratory decisions from birth, giving these babies more chances towards a healthy life,” said MCRI’s Dr. Prue Pereira-Fantini.

Related Links:
MCRI


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.